ClinicalTrials.gg
Not yet recruitingNCT07139912Updated Aug 24, 2025

Prospective, Multicenter, Single-Arm Study of Aortic Arch Pathology Reconstruction

An interventional study of Thoracic Aortic Multi-Branch Stent Graft System in Aortic Arch Disease, sponsored by Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd (part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

A prospective ,multiple center Study about the Safety and Efficacy of the Thoracic Aortic Multi-Branch Stent Graft System, developed and manufactured by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., in patients with aortic arch pathologies.

02

Conditions studied

  • Aortic Arch Disease
03

In context

Lead sponsor

Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 80 years
  2. Diagnosed with aortic arch pathology requiring intervention, including:

    True aortic arch aneurysm

    Pseudoaneurysm of the aortic arch

    Penetrating aortic ulcer involving the arch

  3. Deemed suitable for endovascular repair by the investigating physician
  4. Capable of understanding study objectives, providing written , and complying with follow-up requirements
  5. Anatomic suitability confirmed by CTA:

    Ascending aortic length ≥50 mm

    Ascending aortic diameter ≥26 mm and ≤46 mm

    Proximal landing zone length ≥20 mm

    Brachiocephalic trunk diameter ≥9 mm and ≤19 mm with length ≥20 mm

    Left common carotid artery (LCCA) and left subclavian artery (LSA) diameters ≥5 mm and ≤13 mm

    LCCA length ≥20 mm

    Distance from LSA ostium to left vertebral artery origin ≥20 mm

  6. High surgical risk per investigator assessment OR for open surgery

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women
  2. Connective tissue disorders affecting the aorta (e.g., Marfan syndrome, Ehlers-Danlos syndrome)
  3. Infected aortic pathologies or aortitis (e.g., mycotic aneurysm, Takayasu arteritis)
  4. Prior endovascular repair of ascending aorta/aortic arch
  5. Documented allergy to nitinol, contrast media, or device materials
  6. Severe renal impairment:(Serum creatinine >2×,Excluding dialysis-dependent patients)
  7. Hematologic abnormalities:(WBC \<3×10⁹/L、 \<70 g/L、 \<50×10⁹/L)
  8. Heart transplant recipients
  9. Myocardial infarction or stroke within 3 months
  10. Class IV heart failure
  11. Active systemic infection (e.g., bacteremia, sepsis)
  12. \<12 months
  13. Mechanical aortic valve prosthesis impeding device delivery
  14. Current participation in other interventional trials with primary endpoint pending
  15. Anticipated poor compliance with follow-up
  16. Other for endovascular repair per investigator assessment:Severe vascular stenosis/calcification/tortuosity/Thrombus at landing zones/Inability to cooperate with procedure
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Participant Group/Arm

    Participants will be treated with Thoracic Aortic Multi-Branch Stent Graft System, developed and manufactured by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd

    Device: Thoracic Aortic Multi-Branch Stent Graft System

Interventions

  • DeviceThoracic Aortic Multi-Branch Stent Graft System

    The Thoracic Aortic Multi-Branch Stent Graft Systemm consists of the Single-Branch Aortic Stent-Graft System, the aortic extension stent graft system and the branch stent system.

06

What researchers measure

Primary outcomes

  1. 12-month treatment success rate

    Technical success at the index procedure, without device- or aortic pathology-related mortality or unplanned secondary interventions, and with no evidence of persistent enlargement of the treated aortic segment due to Type I/III endoleaks on 12-month CTA follow-up.

    Time frame: 12-month

  2. 30-day rate of Major Adverse Events (MAE)

    Including all-cause mortality, disabling stroke, persistent paraplegia, renal failure, myocardial infarction, and respiratory failure

    Time frame: 30-day

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Mar 2028, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2025
First posted
Aug 24, 2025
StartEst.
Sep 2025
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2032
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07139912
Responsible party
Sponsor
First posted
Aug 24, 2025
Start date
Sep 2025 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Mar 2032 (estimated)
Last update
Aug 24, 2025

Study contacts

Qingsheng Lu
Contact
luqs@newvascular.cn
021-31162185

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion